Nutrition Intervention During Chemotherapy

NCT ID: NCT01871350

Last Updated: 2025-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-26
• Study Completion Date: 2015-11-03

Brief Summary

Weight loss and muscle wasting commonly occurs in patients with cancer, negatively influencing their quality of life, treatment response and survival. Weight loss has been reported as a side effect of chemotherapy treatment in cancer. Weight changes may be the consequence of energy imbalance and disturbances in protein metabolism (through different factors linked with chemotherapy), such as reduced caloric and protein intake (partly related to depression), poor treatment tolerance, hormonal alterations, systemic inflammation etc. This results in body composition modifications in favor of fat gain and/or lean body mass loss in early stage cancer and loss of both fat mass and lean mass in advanced cancer. Depletion of lean tissue in cancer patients is related to short survival, and decreased skeletal muscle mass and function may result in fatigue and inactivity, which contributes to fat mass changes and can be responsible for chemo-toxicity and increased mortality.

Gains in muscle mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. Recently, the investigators observed that essential amino acid mixtures (EAA) are able to induce protein anabolism in patients with stage III and IV non-small cell lung cancer. Previous experimental research and clinical studies in cachectic conditions (including cancer) indicate that polyunsaturated fatty acids (PUFA) are able to attenuate protein degradation by improving the anabolic response to feeding and by decreasing the acute phase response. Eicosapentaenoic acid (EPA) (in combination with docosahexaenoic acid (DHA)) has been shown to effectively inhibit weight loss in several disease states; however, weight and muscle mass gain was not present or minimal. Recent studies examining the effect of fish oil supplementation in relation to chemotherapy have been inconclusive but found potential beneficial effects on physical performance and increased efficacy of first-line chemotherapy in patients with non-small cell lung cancer.

It is the investigators' hypothesis that supplementation with milk protein (containing essential amino acids) carbohydrate (CHO) mixture in combination with fish oil supplementation will target the metabolic alterations in cancer patients receiving chemotherapy, attenuating the negative effects of chemotherapy on gut function, muscle mass and muscle function, and cognition; and leading to reduced toxicity from chemotherapy.

Detailed Description

For the cancer subjects, the study involves 1 test day prior to a chemotherapy treatment, a 10-week (± 2 weeks) nutritional intervention period at home starting the first day of the chemotherapy treatment, and one test day after this intervention. Chemotherapy in general lasts at least a few months. Recent studies indicate that a 10-week nutritional supplementation period should be long enough to reach significant improvements in nutritional and clinical outcome parameters during chemotherapy. Throughout these 10 weeks the cancer subjects will take the supplements at home. Cancer subjects will be randomly assigned to receive either fish oil or a placebo and protein or a placebo and will take these supplements daily throughout 10 weeks during chemotherapy.

For the healthy subjects, the study will involve one test day (approx. 8 hours).

On the test days, the response to a protein meal will be examined and subjects will receive a mixture of amino acids which are a little bit heavier than normal, called stable isotopes. Subjects will also ingest a sugar drink to assess gut permeability. In total, approximate 120 ml of blood will be drawn on each test day to assess outcome measures. The investigators' will also collect urine over these 8 hours, and cancer subjects are asked to collect a fecal sample the day before the test day.

After completing the nutritional intervention study, cancer subjects will be monitored for up to 6 months via 2 phone calls and through their physician as part of clinical care. Between 6 months and 2 years after completion of the study, information about disease progression (survival) will be obtained from the physician.

Conditions

Cancer Patients Receiving Chemotherapy or Chemoradiotherapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: DOUBLE

Study Groups

Protein and Fish Oil

Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil

High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil

Group Type: EXPERIMENTAL

Daily intake for 10 weeks (+/- 2 weeks)

Intervention Type: DIETARY_SUPPLEMENT

Protein

Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil

High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil

Group Type: EXPERIMENTAL

Daily intake for 10 weeks (+/- 2 weeks)

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil

High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil

Group Type: PLACEBO_COMPARATOR

Daily intake for 10 weeks (+/- 2 weeks)

Intervention Type: DIETARY_SUPPLEMENT

Interventions

Daily intake for 10 weeks (+/- 2 weeks)

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Diagnosed with cancer
• Scheduled for chemotherapy or chemoradiotherapy
• Ability to sign informed consent
• Age 18y and older
• Ability to lie in supine position for 7 hours

• Healthy male or female according to the investigator's or appointed staff's judgment
• Age 18 years or older
• No diagnosis of cancer

Exclusion Criteria

• Presence of fever within the last 3 days
• BMI > 38 kg/m2 (healthy controls only)
• Untreated metabolic diseases including hepatic or renal disorder
• Presence of acute illness or metabolically unstable chronic illness
• Use of protein or amino acid containing nutritional supplements within 5 days of first test day
• Known hypersensitivity to fish and/or shellfish, Swanson EFAs Super EPA Fish oil or any of its ingredients, Swanson EFAs Certified Organic Extra Virgin Olive oil or any of its ingredients, Smartfish Nutrifriend or any of its ingredients (Cancer subjects only)
• Use of supplements containing EPA+DHA 3 months prior to the first test day
• Any other condition according to the PI or nurse that would interfere with the study or safety of the patient
• Failure to give informed consent
• (Possible) pregnancy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Texas A&M University

OTHER

Sponsor Role: lead

Responsible Party

Marielle PKJ Engelen, PhD

PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Marielle PKJ Engelen, PhD

Role: PRINCIPAL_INVESTIGATOR

Texas A&M Univeristy

Locations

Texas A&M University

College Station, Texas, United States

Countries

United States

Other Identifiers

2012-0504

Identifier Type: -

Identifier Source: org_study_id